本文選題：二甲雙胍　切入點(diǎn)：絕經(jīng)后骨質(zhì)疏松癥　出處：《山西醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討不同濃度二甲雙胍對(duì)去勢大鼠脛骨的骨密度(Bone mineral density,BMD)和骨生物力學(xué)的影響,探討通過應(yīng)用二甲雙胍干預(yù)雙側(cè)卵巢摘除大鼠,檢測血清中晚期糖基化終產(chǎn)物變化從而確定其調(diào)控骨代謝的可行性,從而為骨質(zhì)疏松癥的臨床藥物防治提供依據(jù)。方法:使用SD雌鼠通過行假手術(shù)或雙側(cè)卵巢摘除術(shù)建立對(duì)照組模型(Sham組)及停經(jīng)后骨質(zhì)疏松癥模型(OVX組),分為4組,分別是Sham組,OVX組,OVX+50 mg/kg/day二甲雙胍組,OVX+100 mg/kg/day二甲雙胍組。3月后給予不同劑量二甲雙胍灌胃,Sham組、OVX組給予相應(yīng)劑量0.9%生理鹽水,OVX+50mg/kg/day二甲雙胍組、OVX+100 mg/kg/day二甲雙胍組分別按50 mg/kg/day、100 mg/kg/day灌胃二甲雙胍。3月后處死大鼠,取血清、脛骨標(biāo)本,應(yīng)用雙能X線、生物力學(xué)、組織學(xué)方法檢測不同組別大鼠骨質(zhì)差異,應(yīng)用酶聯(lián)免疫吸附試驗(yàn)(ELISA)檢測并比較各組大鼠血清中晚期糖基化終產(chǎn)物(AGEs)表達(dá)水平及差異。結(jié)果:與Sham組相比,OVX組大鼠的脛骨骨質(zhì)呈現(xiàn)明顯的疏松多孔樣,骨密度明顯降低(P0.05),彈性模量和最大載荷也顯著下降(P0.05),血清中AGEs含量明顯升高(P0.05),灌胃二甲雙胍后,脛骨質(zhì)量有所改善,骨小梁分布較OVX組密集,骨密度升高(P0.05),彈性模量和最大載荷也增加(P0.05),同時(shí)血清中AGEs含量較OVX組顯著降低(P0.05),但均尚未達(dá)到Sham組水平(P0.05)。OVX+50 mg/kg/day二甲雙胍組與OVX+100 mg/kg/day二甲雙胍組實(shí)驗(yàn)結(jié)果比較發(fā)現(xiàn):兩組大鼠血清中AGEs含量接近(P0.05),骨質(zhì)量、骨密度無明顯差異(P0.05),但彈性模量和最大載荷表現(xiàn)出劑量相關(guān)性(P0.05)。結(jié)論:1、二甲雙胍可提高去勢大鼠骨密度及骨生物力學(xué)參數(shù),具有改善停經(jīng)后骨質(zhì)疏松性骨折的作用。2、二甲雙胍可能通過降低絕經(jīng)后骨質(zhì)疏松大鼠血清中的AGEs含量進(jìn)而改善骨代謝。
[Abstract]:Objective: to investigate the effects of metformin at different concentrations on bone mineral density (BMD) and bone biomechanics in ovariectomized rats, and to explore the effect of metformin on bilateral ovariectomized rats. To determine the feasibility of regulating bone metabolism by detecting the changes of advanced glycation end products in serum. Methods: SD female rats were used to establish control group by sham-operation or bilateral ovariectomies) and postmenopausal osteoporosis model OVX group were divided into 4 groups. OVX 50 mg / kg / kg / day metformin group OVX 100 mg/kg/day metformin group respectively. After March, different doses of metformin were given intragastrically to the 0.9% normal saline group with 50 mg / kg mg/kg/day / kg metformin group, and the OVX 100 mg/kg/day metformin group were given OVX 100 mg/kg/day metformin group respectively, after March, the OVX group received 50 mg / kg of normal saline and 50 mg / kg 路kg / day metformin group respectively, and the OVX 100 mg/kg/day metformin group was given OVX100 mg/kg/day metformin group respectively after March. The rats were given metformin at 50 mg / kg / kg / 100 mg/kg/day. After March, the rats were killed. Serum and tibia samples were collected and bone difference of different groups of rats was detected by dual-energy X-ray, biomechanics and histology. Enzyme linked immunosorbent assay (Elisa) was used to detect and compare the expression of advanced glycation end products (ages) in the serum of rats in each group. Results: compared with Sham group, the tibial bone of rats in OVX group was obviously porous and porous. The bone mineral density (BMD) decreased significantly (P 0.05), the modulus of elasticity and the maximum load also decreased significantly (P 0.05). The content of AGEs in serum increased significantly (P 0.05). After intragastric administration of metformin, the tibia quality was improved, and the distribution of bone trabeculae was denser than that in the OVX group. The content of AGEs in serum was significantly lower than that in OVX group, but it was still not up to the level of Sham group. OVX 50 mg/kg/day metformin group and OVX 100 mg/kg/day metformin group were compared with OVX 100 mg/kg/day metformin group. The content of AGEs in serum of the two groups was close to that of P0. 05, and the bone mass of the two groups was higher than that of the control group. There was no significant difference in bone mineral density (BMD), but there was a dose-dependent correlation between the modulus of elasticity and the maximum load. Conclusion the bone mineral density and bone biomechanical parameters of ovariectomized rats can be increased by 1: 1 and metformin. Metformin may improve bone metabolism by reducing serum AGEs content in postmenopausal osteoporosis rats.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R580

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蘇青;;二甲雙胍降糖作用的分子機(jī)制[J];中華內(nèi)分泌代謝雜志;2016年09期

2 申甜;喻明;章志建;徐碧林;張翠平;;二甲雙胍與西格列汀對(duì)非酒精性脂肪肝病大鼠肝臟FGF21及SREBP-1c mRNA表達(dá)的影響[J];實(shí)用藥物與臨床;2016年05期

3 鄭仲萍;田峰;鄭志剛;張國慶;郭鋒;郭杏花;;二甲雙胍聯(lián)用六味地黃丸對(duì)T2DM并NAFLD患者血清病情相關(guān)分子含量的影響[J];海南醫(yī)學(xué)院學(xué)報(bào);2016年10期

4 劉超;李春睿;徐書杭;;二甲雙胍對(duì)甲狀腺疾病的影響及其臨床處理[J];藥品評(píng)價(jià);2015年09期

5 陳娟;;探究二甲雙胍的心血管保護(hù)作用[J];中西醫(yī)結(jié)合心血管病電子雜志;2015年07期

6 武紅琴;阮祥燕;盧永軍;田玄玄;張穎;劉玉蘭;甄潔;Diethelm Wallwiener;Alfred O.Mueck;;綜合管理下達(dá)英-35與達(dá)英-35聯(lián)合二甲雙胍治療多囊卵巢綜合征的療效研究[J];首都醫(yī)科大學(xué)學(xué)報(bào);2014年04期

7 母義明;紀(jì)立農(nóng);寧光;李光偉;單忠艷;李焱;孫子林;李延兵;趙家軍;王衛(wèi)慶;朱大龍;洪天配;童南偉;周智廣;鄒大進(jìn);劉超;李強(qiáng);郭立新;彭永德;陳璐璐;肖新華;余學(xué)鋒;王佑民;姬秋和;李啟富;李春霖;時(shí)立新;李益明;石勇銓;趙志剛;楊婉花;紀(jì)立偉;趙榮生;吳久鴻;;二甲雙胍臨床應(yīng)用專家共識(shí)[J];藥品評(píng)價(jià);2014年15期

8 陳愉;;阿卡波糖聯(lián)合二甲雙胍治療2型糖尿病伴高血脂癥療效觀察[J];中國現(xiàn)代藥物應(yīng)用;2013年14期

9 甄東戶;劉麗娟;湯旭磊;成建國;;二甲雙胍對(duì)骨代謝的影響[J];中國臨床藥理學(xué)與治療學(xué);2012年11期

10 龐曉娜;胡予;;二甲雙胍與骨質(zhì)疏松的關(guān)系[J];中國骨質(zhì)疏松雜志;2012年08期

相關(guān)博士學(xué)位論文 前2條

1 劉瑛;二甲雙胍通過mTOR信號(hào)通路對(duì)Hacat角質(zhì)形成細(xì)胞增殖的影響[D];山東大學(xué);2015年

2 許國順;二甲雙胍對(duì)造血免疫系統(tǒng)輻射損傷防護(hù)作用及分子機(jī)制研究[D];北京協(xié)和醫(yī)學(xué)院;2013年

，

本文編號(hào)：1588557